Haemonetics Corporation (HAE) - Form 8-K Summary
Business Context and Reporting Period
Haemonetics Corporation, a Massachusetts-based registrant, filed this Current Report on Form 8-K on May 7, 2026. The filing announces the issuance of a press release detailing financial results for the fourth quarter and the full fiscal year ended March 28, 2026.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
As the specific financial figures and comparative data are located in the attached press release rather than the body of this 8-K, no material changes versus the prior comparable period can be summarized from the source text provided.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific guidance, outlook, management commentary, risks, or unusual items are detailed within the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 7, 2026) for actual Q4 and full-year 2026 financial figures.
- Verify specific revenue, net income, and cash flow numbers against the attached press release.
- Check for any forward-looking guidance or updated fiscal year 2027 projections in the press release.
- Confirm the fiscal year-end date of March 28, 2026, for accurate period comparison.